HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.
作者： Mary L. Disis , Martin A. Cheever
DOI: 10.1016/S0065-230X(08)60103-7
关键词:
摘要: The HER-2/neu oncogenic protein is a tumor antigen. Some patients with cancer have preexistent immune response directed against the protein. Effective vaccines targeting will be able to boost this immunity potentially therapeutic levels. In addition, HER-2/neu-directed monoclonal antibody therapy has been effective in eradicating malignancy animal models and shown benefit treatment of human HER-2/neu-overexpressing cancers. This review outlines studies that define HER-2/neu-specific overviews current vaccine strategies for generating or augmenting neu-specific immunity. potential problems associated eliciting are addressed, including question precipitating autoimmune toxicity "self" -protein mechanisms immunological escape may play role preventing function response. Finally, antibody-based therapies overviewed. prototype antigen groups investigating innovative modifications technology, cutting edge being contemplated clinical use malignancy. Immune-based treatments designed target soon give oncologist new weapons, biologically relevant tumor-related protein, which fight cancer.
sci-hub.se 参考文章(98)
Carlos Cordon-Cardo, Michael F. Press, Dennis J. Slamon, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. ,vol. 5, pp. 953- 962 ,(1990)
Drebin Ja, Link Vc, Greene Mi, Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. ,vol. 2, pp. 273- ,(1988)
J C Sarup, H M Shepard, B M Fendly, M T Lipari, K L King, A Ullrich, R M Johnson, M A Napier, Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth regulation. ,vol. 1, pp. 72- 82 ,(1991)
M D Pegram, R J Pietras, S B Howell, V R Chazin, B M Fendly, D J Slamon, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. ,vol. 9, pp. 1829- 1838 ,(1994)
R.R. Beerli, W. Wels, N.E. Hynes, Intracellular expression of single chain antibodies reverts ErbB-2 transformation Journal of Biological Chemistry. ,vol. 269, pp. 23931- 23936 ,(1994) , 10.1016/S0021-9258(19)51027-4
Ituo Miyazaki, Shigekazu Ohoyama, Itasu Ninomiya, Akio Yamaguchi, Motohiro Tanaka, Yutaka Yonemura, Takuma Sasaki, Yoshio Endou, Sachio Fushida, Hironobu Kimura, Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Research. ,vol. 51, pp. 1034- 1038 ,(1991)
Salvatore Andreola, Maria I. Colnaghi, Serenella M. Pupa, Sylvie Ménard, Antibody Response against the c-erbB-2 Oncoprotein in Breast Carcinoma Patients Cancer Research. ,vol. 53, pp. 5864- 5866 ,(1993)
J C Reece, S J Rodda, H M Geysen, Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. Journal of Immunology. ,vol. 151, pp. 6175- 6184 ,(1993)
I Yoshino, T J Eberlein, A S Parikh, G E Peoples, P S Goedegebuure, H K Lyerly, A F Gazdar, J M DiMaio, HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Research. ,vol. 54, pp. 3387- 3390 ,(1994)
Vincenzo Bronte, Nicholas P. Restifo, Steven A. Rosenberg, Bernard Moss, Kari R. Irvine, Ronald S. Chamberlain, Jay B. Rao, Miles W. Carroll, IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. Journal of Immunology. ,vol. 156, pp. 3357- 3365 ,(1996)